Cytiva opens Swiss manufacturing facility and Center of Excellence for cell and gene therapies

By Rachel Arthur contact

- Last updated on GMT

Pic: Cytiva
Pic: Cytiva

Related tags: Cytiva, Cell therapy manufacturing, Cell therapy, cell and gene therapy, Switzerland

Cytiva is opening a new 7,400m² manufacturing facility in Grens, Switzerland this month: which will serve as a center of excellence for the company’s cell and gene therapy business as well as a being a base for European customer training programs.

The site will manufacture single use kits for the Sepax and Sefia cell processing systems, as well as consumables for Xuri cell expansion systems.

The facility will quadruple Cytiva’s existing capacity for manufacturing Sefia, Sepax, and Xuri consumable products with two new ISO class 7 cleanrooms, ensuring that increased future demand can be met.

Facility designed with sustainability in mind

The design of the facility adopts GMP principles from raw materials entering the building, through the manufacturing process, to the shipment of finished products.

The new site has been built to Swiss Minergie standards, a sustainable building standard recognized globally for its effectiveness in achieving lower energy and resource consumption.

Building to this standard provides high-grade, air-tight building envelopes and the continuous renewal of air in the building using an energy-efficient ventilation system. The building is powered by 100% renewable electricity and has roof mounted solar panels. It also has five distinct HVAC systems that optimize environmental conditions in each functional area. Cytiva is investigating the use of ‘dynamic’ cleanroom controls which would further reduce power usage by up to 60%.

A R&D facility is located on the first floor, which consists of several laboratories designed for multidisciplinary engineering and cell biology processing capabilities. The customer training center, located on the second floor, is a fully equipped 100m² BSL2 laboratory that will enable process and application training with Cytiva instruments, consumables, and software. Cytiva associates will also be able to use this facility to develop knowledge and skills on current and future products and processes.

Catarina Flyborg, vice president, Cell and Gene Therapy, Cytiva said: “Cell and gene therapies have the potential to change the global healthcare landscape. Our new facility in Grens will enable us to meet global demand for our products, while working with our customers to meet their immediate training and development needs. This facility brings us another step closer to our vision where access to life-changing therapies transforms human health.”

The site will be home to 250 associates. An opening ceremony will be held on May 31 followed by a LinkedIn Live Broadcast on June 2.

Cytiva’s existing site in Eysins will continue operations through 2023, while full production transfers to the new site in Grens.

 

Related topics: Upstream Processing

Related news

Show more